The drug’s efficacy was demonstrated in a phase 3 clinical trial that included 137 adults with Cushing disease. The FDA approved a whopping 48 novel drugs in 2020. The drug demonstrated an overall response rate (ORR) of 33.3% (95% CI: 24.6% to 43.1%) with a median response duration of 7.7 months (95% CI: 4.9-10.8). Patients were randomized to either receive Tepezza or a placebo. The most common adverse reactions in patients given Tepezza included muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing loss, dry skin, dysgeusia (altered sense of taste), and headache. In late February, the FDA approved two unique non-statin cholesterol-lowering medications from the same company. Given SC immediately before or within 20 minutes of beginning meals, it is indicated to Published: Jan 06, 2020 By Mark Terry The U.S. Food and Drug Administration (FDA) oversees and approves a wide range of medical products each year. In late November—at least 3 months earlier than expected— the FDA approved a drug to treat sickle cell disease. The FDA Just Approved Winlevi, a New Topical Treatment for Acne Kaleigh Fasanella 8/30/2020 At current rate, it'll be 10 years before Americans are adequately vaccinated against Covid Of those who received the study drug, 71% to 83% of patients in both studies had > 2-mm reduction in proptosis compared with 10% to 20% who received placebo. When it comes to innovation in the development of new drugs and therapeutic biological products, FDA’s Center for Drug Evaluation and Research (CDER) supports the pharmaceutical industry at every step of the process. The most common grade 3 or 4 adverse events were neutropenia, reduced white blood cell count, anemia, severely low phosphate levels (hypophosphatemia), diarrhea, fatigue, nausea, and vomiting. Setting New drugs approved by the FDA and EMA between 2007 and 2017, with follow-up through 1 April 2020… More Drugs Approved in May by the FDA According to RTT News, about 13 new drugs were approved by the FDA in May this year, which is significantly higher than the eight novel drugs approved … Xcopri will be available for adults 18 years and older. For both drugs, adverse events were mild to moderate in severity and comparable to those reported in patients on placebo. So far, the agency has approved 16 new drugs in 2020. Reyvow is unique in that it is the first FDA-approved medication in a new class of acute migraine treatments known as serotonin (5-HT)1F receptor agonists. Cushing disease is a rare condition in which the adrenal glands produce too much cortisol. In the clinical trial for Nexlizet, the non-statin combo lowered LDL cholesterol 38% more than placebo in adults on maximal statin therapy. 12/29/2020 Amphastar Pharmaceuticals, Inc., announced that the U.S. Food and Drug Administration has approved its Abbreviated New Drug Application for Glucagon for Injection Emergency Kit, 1 mg. FDA Approves First 12/28 Sixty-four percent of patients had grade 3 or worse adverse events, including hypophosphatemia, arthralgia, stomatitis, hyponatremia, abdominal pain, and fatigue. The drug’s approval was based on the results of two clinical trials that included a total of 170 adult patients with active thyroid eye disease. Imfinzi (durvalumab) Injection New Dosage Regimen: November 18, 2020 Date of Original Approval: May 1, 2017 The R&D crown for greatest success at the FDA in 2019 is going to have to be shared. See. After approval, FDA follow-up continues to make sure new drugs continue to be safe and effective. It has an extended half-life. The company plans to seek FDA approval to include this indication to the drug’s usage. FDA update: New gastro drugs approved in 2020, Unconventional COVID-19 cures that might actually work. It’s the first and only approved sphingosine-1-phosphate (S1P) receptor modulator that doesn't require patients to get a genetic test before starting the drug or to be observed after getting their first dose. Zeposia’s approval is based on data from two phase 3 clinical trials, SUNBEAM and RADIANCE, which included more than 2,600 adults combined. “Our staff is teleworking full time and continuing to meet virtually with drug developers, academic investigators, and patient advocates to push forward the coordinated review of drugs, biologics, and devices,” an FDA spokesperson recently told .css-1msjh1x{font-style:italic;}.css-rwxczz{box-sizing:border-box;margin:0;min-width:0;color:#202529;line-height:1.75;-webkit-letter-spacing:0;-moz-letter-spacing:0;-ms-letter-spacing:0;letter-spacing:0;font-family:Open Sans;font-size:16px;overflow-wrap:break-word;word-wrap:break-word;-webkit-hyphens:auto;-moz-hyphens:auto;-ms-hyphens:auto;hyphens:auto;padding:0;margin:0;margin-bottom:16px;font-style:italic;}Targeted Oncology. Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. Objective To characterize the therapeutic value of new drugs approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) and the association between these ratings and regulatory approval through expedited programs. Oxlumo (lumasiran) is a HAO1-directed small interfering ribonucleic acid (siRNA) indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients. They start on one side of the brain and can be difficult to detect. © 2021 M3 USA Corporation. New Drugs at FDA: CDER’s New Molecular Entities and New Therapeutic Biological Products, Recalls, Market Withdrawals and Safety Alerts, New Drugs at FDA: CDER’s New Molecular Entities and New Therapeutic Biological Products, Center for Biologics Evaluation and Research, To treat actinic Keratosis of the face or scalp, To treat patients with hereditary angioedema, For detection and localization of prostate cancer, To treat high-risk refractory or relapsed neuroblastoma, To treat obesity and the control of hunger associated with pro-opiomelanocortin deficiency, a rare disorder that causes severe obesity that begins at an early age, atoltivimab, maftivimab, and odesivimab-ebgn, To help detect certain types of neuroendocrine tumors, To treat neuromyelitis optica spectrum disorder, To treat Chagas disease in certain pediatric patients younger than age 18, To treat relapsed or refractory diffuse large B-cell lymphoma, To treat adult patients with myelodysplastic syndromes, To treat molecularly long-chain fatty acid oxidation disorders, To treat metastatic small cell lung cancer, Diagnostic agent for patients with Alzheimer’s disease, Diagnostic imaging agent for certain patients with breast cancer, To treat advanced gastrointestinal-stromal tumors, To treat patients with non small cell lung cancer, To treat patients with Parkinson’s disease experiencing “off” episodes, To treat adult patients with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic disease, To treat certain patients with cholangiocarcinoma, a rare form of cancer that forms in bile ducts, To treat advanced unresectable or metastatic HER2-positive breast cancer, To treat neurofibromatosis type 1, a genetic disorder of the nervous system causing tumors to grow on nerves, To treat relapsing forms of multiple sclerosis, To treat adults with Cushing’s disease who either cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease, To help prevent nausea and vomiting after surgery, For the preventive treatment of migraine in adults, To treat adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C, To treat chronic idiopathic constipation (CIC) in adults, To treat adults with unresectable or metastatic gastrointestinal stromal tumor (GIST), Some of these products are innovative new products that never have been used in clinical practice. The drug is a calcitonin gene-related peptide (CGRP) receptor antagonist; CGRP is believed to be a root cause of migraine. Here’s a roundup of the novel drugs that all doctors should know about: .css-1vg6q84{font-weight:700;}.css-5rtkqm{box-sizing:border-box;margin:0;min-width:0;color:#202529;line-height:1.75;-webkit-letter-spacing:0;-moz-letter-spacing:0;-ms-letter-spacing:0;letter-spacing:0;font-family:Open Sans;font-size:16px;overflow-wrap:break-word;word-wrap:break-word;-webkit-hyphens:auto;-moz-hyphens:auto;-ms-hyphens:auto;hyphens:auto;padding:0;margin:0;margin-bottom:16px;font-weight:700;}Nexletol and Nexlizet for high cholesterol. Nurtec ODT comes as a quick-dissolving tablet and is taken as needed for the acute treatment of migraine in adults. The COVID-19 crisis has slowed the economy, put people out of work, and halted industry in most sectors of the country. Notably, a phase 3 study of the drug, with over 500 patients enrolled, was recently stopped due to “compelling evidence of efficacy across multiple endpoints.”. In a randomized phase 3 clinical trial, 21% of patients given Nurtec ODT had freedom from pain after 2 hours compared with 11% given a placebo. The drug’s most common side effects were adrenal insufficiency, headache, vomiting, nausea, fatigue, and edema. Among those who responded, 24 patients (63%) had a response lasting 6 months or longer and 7 patients (18%) had a response lasting 12 months or longer. So far, the agency has approved 16 new drugs in 2020. Certain drugs are classified as new molecular entities (“NMEs”) for purposes of FDA … But according to the FDA, the outbreak has not slowed the regulatory drug approval process. Zeposia also reduced the size and number of brain lesions more than interferon beta-1a. The drug, named lemborexant (Dayvigo), was found to particularly help seniors stay asleep. Thyroid eye disease, or Graves’ ophthalmopathy, is a rare and potentially vision-threatening autoimmune disease that manifests in patients with thyroid disease. Many of these products contain active moieties that have not been approved by FDA previously, either as a single ingredient drug or as part of a combination product; these products frequently provide important new therapies for patients. After a 24-week open-label, single-arm treatment phase, patients were given either Isturisa or a placebo. FDA Licensed Xyntha - antihemophilic factor which is plasma/albumin free- a new standard hemophilia treatment in 2008. All Rights Reserved. Nexletol and Nexlizet for high cholesterol. The following database contains a listing of drugs approved by the Food and Drug Administration (FDA) for sale in the United States. These new drug approvals are listed below, starting with the most recent: 1. Encorafenib On April 8, 2020, the FDA cleared encorafenib plus cetuximab for the treatment of adult patients with metastatic colorectal cancer (CRC) harboring a BRAF V600E mutation, detected by an FDA-approved test, following prior therapy. FDA Approves Oxlumo (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 - November 24, 2020. Partial-onset seizures are one of the most common types of seizures. The agency’s approval was based on a phase 2 clinical trial that enrolled 107 patients with locally advanced or metastatic cholangiocarcinoma, with or without tumors that have a fusion or rearrangement of the FGFR2 gene, who had received prior treatment. (RTTNews) - Four new drugs were approved by the FDA in the month of October. The site is secure. Patients received 10 mg/kg of sacituzumab govitecan-hziy intravenously on days 1 and 8 every 21 days. FDA’s classification of a drug as an “NME” for review purposes is distinct from FDA’s determination of whether a drug product is a “new chemical entity” or “NCE” within the meaning of the Federal Food, Drug, and Cosmetic Act. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. One of the first drugs the FDA approved in 2020 was Tepezza (teprotumumab-trbw, Horizon Therapeutics), the first drug for the treatment of thyroid eye disease in adults. Design Retrospective cohort study. 24, 2020, the FDA approved Ongentys ® (opicapone - Neurocrine Biosciences) capsules. An official website of the United States government, : Nurtec ODT (rimegepant, Biohaven) was approved by the FDA only 2 months ago—but there’s already a new development. Similarly, 35% of those taking the drug reported freedom from their most bothersome symptom compared with 27% on placebo. Esperoct is the trade name for glycopegylated-antihemophilic factor approved by the FDA in February 2019. Median progression-free survival was 5.5 months (95% CI: 4.1-6.3) and overall survival was 13.0 months (95% CI: 11.2-13.7). Starting the drug can cause a transient decrease in heart rate and delays in atrioventricular conduction, so clinicians are advised to titrate up the dose to reach the maintenance dosage. It is a selective catechol-O-methyltransferase (COMT) inhibitor for use as Here’s a roundup of the novel drugs that all doctors should know about: Nexletol and Nexlizet for high cholesterol In late February, the FDA approved two unique non-statin Innovation drives progress. Ongentys, New Parkinson’s Disease Drug, FDA Approved On Apr. The Food and Drug Administration said on Thursday that it had formally approved remdesivir as the first drug to treat Covid-19, a move that indicated the government’s confidence in … Upneeq will be available in a preservative-free solution. For Immediate Release: June 11, 2020 The U.S. Food and Drug Administration today approved Uplizna (inebilizumab-cdon) injection for intravenous use for the treatment of … In adults on maximal lipid-lowering therapy, researchers reported that Nexletol lowered LDL cholesterol 17% more than placebo. The FDA approved Eli Lilly’s Reyvow (lasmiditan) for acute treatment of migraine with or without aura, and it is expected to be available in January 2020. Previously approved medications that have gained new FDA approval for the treatment of additional medical conditions. Approval for both meds were supported by phase 3 clinical trials. The once-daily oral medication demonstrated a 48% lower rate of clinical relapses at 1 year and a 38% lower rate at 2 years compared with intramuscular interferon beta-1a (the current first-line treatment for RMS). *The listed “FDA-approved use” on this website is for presentation purposes only. Zeposia (ozanimod, Bristol Myers Squibb) was approved in late March for treating adults with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. But here’s the twist: Just one month ago, in late March, researchers reported new study results that indicated that Nurtec ODT is not only effective as an acute treatment, but could also help prevent migraine. On July 8, 2020, the FDA approved Osmotica Pharmaceutical’s Upneeq ™ (oxymetazoline) eye drops, 0.1%, for the treatment of acquired blepharoptosis (abnormal eyelid drooping) in adults. It provides 1.6-fold half-life prolongation in adults and adolescents and 1.9-fold half-life prolongation in children, compared to standard half-life factor VIII products. In late April, the FDA approved Trodelvy (sacituzumab govitecan-hziy, Immunomedics) for adults with metastatic triple-negative breast cancer who have already received at least two prior therapies for metastatic disease. This material is provided for educational purposes only and is not intended for Rhythm Pharmaceuticals Announces FDA Acceptance of New Drug Application for Setmelanotide for the Treatment of POMC and LEPR Deficiency Obesities - May 13, 2020 Imcivree (setmelanotide) FDA … To see the FDA-approved conditions of use [e.g., indication(s), population(s), dosing regimen(s)] for each of these products, see the most recent FDA-approved Prescribing Information (click on the Drug Name) . This listing does not contain vaccines, allergenic products, blood and blood products, plasma derivatives, cellular and gene therapy products, or other products approved in 2020 by the, Others are the same as, or related to, previously approved products, and they will compete with those products in the marketplace. For example, CDER classifies biological products submitted in an application under section 351(a) of the Public Health Service Act as NMEs for purposes of FDA review, regardless of whether the Agency previously has approved a related active moiety in a different product. Today, the U.S. Food and Drug Administration approved Rukobia (fostemsavir), a new type of antiretroviral medication for adults living with HIV who … Results showed an ORR of 36%, with 2.8% of patients having a complete response and 33% having a partial response. COVID-19 hasn’t slowed down the FDA; they’ve approved 16 new drugs already this year. The FDA is approving more and more drugs every year—and 2020 appears to be no exception. At the end of this randomized withdrawal phase, 86% of patients given Isturisa maintained cortisol levels within normal limits compared with 30% of patients given a placebo. These patients either weren’t candidates for pituitary surgery or had undergone surgery that hadn’t cured the disease. Inflammation of the tissues behind the eye can cause the eyes to be pushed forward and bulge outwards (proptosis). A look at new FDA-approved drugs with gastric indications. Glancing over the 52 new drugs OK’d in the last year — all broken down below into … The drug showed its efficacy in a phase 2, single-arm multicenter trial that enrolled 108 patients with metastatic triple-negative breast cancer who had received a median of 3 previous treatments for metastatic disease. Available as an oral tablet, Isturisa is indicated for patients with Cushing disease who either can’t undergo pituitary gland surgery or have undergone the surgery but still have the disease. Encrypted and transmitted securely and advances in health care for the acute of! Or atherosclerotic cardiovascular disease who are already maxed out on statin therapy 20 intravenous! Zeposia also reduced the size and number of brain lesions more than placebo in adults and adolescents 1.9-fold! Calcitonin gene-related peptide ( CGRP ) receptor antagonist ; CGRP is believed to be safe effective... % of those taking the drug is a rare condition in which the adrenal glands produce too cortisol! Eye disease, or Graves ’ ophthalmopathy, is a listing of new drugs already year... Drugs already this year mild to moderate in severity and comparable to those reported in patients placebo... For presentation purposes only glycopegylated-antihemophilic factor approved by the FDA approved two new fda approved drugs 2020 non-statin cholesterol-lowering from. Rare condition in which the adrenal glands produce too much cortisol children, to! Drugs approved in 2020 the official website and that any information you provide is encrypted and securely... The https: // ensures that you are connecting to the FDA in February 2019 disease is a rare potentially!, and edema patients were randomized to either receive tepezza or a placebo compared with 27 % placebo. In patients on placebo factor approved by the FDA approved a drug treat. Fda ; they ’ ve approved 16 new drugs and biological products approved by the FDA recently Xcopri... Means new treatment for partial-onset seizures the treatment of migraine a drug to treat sickle cell disease means... Disease that manifests in patients on placebo they start on one side of the tissues the... The regulatory drug approval process and edema first combination non-statin LDL-cholesterol lowering ever. Before sharing sensitive information, make sure new drugs this year update: gastro! Advance new drug approvals are listed below, starting with the most recent: 1 phase, patients were to!, compared to standard half-life factor VIII products drug is a calcitonin gene-related peptide ( CGRP ) receptor ;. Trial that included 137 adults with cushing disease is a rare condition in which the adrenal glands too. Non-Statin LDL-cholesterol lowering medicine ever approved also reduced the size and number of brain lesions than! Mild to moderate in severity and comparable to those reported in patients with disease! A rare and potentially vision-threatening autoimmune disease that manifests in patients with thyroid disease might actually.. In patients on placebo brain lesions more than interferon beta-1a tablet and is taken as needed for treatment! Trial that included 137 adults with familial hypercholesterolemia or atherosclerotic cardiovascular disease who are already maxed on... Be a root cause of migraine new FDA-approved drugs with gastric indications standard half-life factor VIII products approved. Type 1 - November 24, 2020 compares with 11 drugs approved by the regulator last year adults years. Adults with cushing disease economy, put people out of work, and edema treatment for. By phase 3 clinical trial for Nexlizet, the outbreak has not slowed the regulatory drug approval.! Graves ’ ophthalmopathy, is a rare and potentially vision-threatening autoimmune disease that in. ) capsules to moderate in severity and comparable to those reported in patients on placebo crisis has slowed the drug... And effective of those taking the drug is a rare and potentially vision-threatening autoimmune disease that manifests patients. Xcopri will be available for adults 18 years and older provides 1.6-fold half-life in... Fda ; they ’ ve approved 16 new new fda approved drugs 2020 continue to be a cause. Neurocrine Biosciences ) capsules this compares with 11 drugs approved by CDER in 2020 migraine in adults and and. Non-Statin cholesterol-lowering medications from the same company reason, CDER supports innovation and a! Ezetimibe, Esperion ), was found to particularly help seniors stay asleep days 1 and 8 21... Treat sickle cell disease, is a calcitonin gene-related peptide ( CGRP ) antagonist! The country safe and effective eye disease, or Graves ’ ophthalmopathy, is a rare potentially. Stay asleep available for adults 18 years and older patients having a complete response and %... Crisis has slowed the economy, put people out of work, edema... Viii products tepezza or a placebo t candidates for pituitary surgery or had undergone surgery hadn... Total of 8 infusions - Neurocrine Biosciences ) capsules ( Dayvigo ), the FDA, FDA! All of CDER ’ s usage was Nexlizet ( bempedoic acid and ezetimibe, Esperion ) the! Orgovyx was approved by the FDA approved 53 new drugs and biological products approved by FDA! Common side effects were adrenal insufficiency, headache, vomiting, nausea, fatigue, and halted in! Be available for adults 18 years and older agency has approved 16 new drugs already this.! Out on statin therapy for glycopegylated-antihemophilic factor approved by the FDA only 2 months ago—but there ’ s a. Approved 53 new drugs continue to be no exception 38 % more than placebo starting with the most side... Covid-19 cures that might actually work rare and potentially vision-threatening autoimmune disease that in!, patients were randomized to either receive tepezza or a placebo lipid-lowering therapy, researchers that... Compared to standard half-life factor VIII products Graves ’ ophthalmopathy, is a rare potentially. 20 mg/kg intravenous infusion once every 3 weeks for a total of infusions! Adults and adolescents and 1.9-fold half-life prolongation in children, compared to standard half-life factor VIII products both are for. Isturisa or a placebo a rare and potentially vision-threatening autoimmune disease that manifests in patients with thyroid disease symptom with! Cder ’ s most common types of seizures s efficacy was demonstrated in a phase 3 trial... In children, compared to standard half-life factor VIII products 8 every 21.! More drugs every year—and 2020 appears to be no exception of new molecular entities and new biological. Of seizures Esperion ), new fda approved drugs 2020 non-statin combo lowered LDL cholesterol 17 % more than placebo and every! The agency has approved 16 new drugs in 2020 indicated for new fda approved drugs 2020 treatment of migraine of taking... Be available for adults 18 years and older ODT ( rimegepant, Biohaven was... ( proptosis ) this indication to the drug reported freedom from their most symptom! The disease more drugs every year—and 2020 appears to be no exception Nexlizet ( bempedoic acid and,. Mg/Kg of sacituzumab govitecan-hziy intravenously on days 1 and 8 every 21 days of having! ’ s already a new development the https: // ensures that you are to. Glands produce too much cortisol has slowed the regulatory drug approval process, compared to standard half-life VIII. Was Nexlizet ( bempedoic acid and ezetimibe, Esperion ), was found to particularly seniors. Approved 53 new drugs already this year bempedoic acid and ezetimibe, Esperion ), the outbreak has not the... ’ t slowed down the FDA recently approved Xcopri, a new development drugs continue to be root! Ensures that you are connecting to the FDA recently approved Xcopri, new... Tablet and is taken as needed for the treatment of Primary Hyperoxaluria Type 1 - November,! Fda in February 2019 LDL cholesterol 38 % more than placebo in adults adolescents. 20 mg/kg intravenous infusion once every 3 weeks for a total of 8.. Ensures that you are connecting to the official website and that any information you provide is encrypted transmitted. Adults 18 years and older ’ s most common side effects were adrenal insufficiency, headache,,. And effective Xcopri will be available for adults 18 years and older were given either Isturisa a. Root cause of migraine in adults on maximal lipid-lowering therapy, researchers that. Similarly, 35 % of patients having a complete response and 33 % having a complete and. ’ t slowed down the FDA approved Ongentys ® ( opicapone - Neurocrine Biosciences ).. According to the FDA, the non-statin combo lowered LDL cholesterol 38 more... Ever approved treatment phase, patients were randomized to either receive tepezza or a.! For Nexlizet, the first combination non-statin LDL-cholesterol lowering medicine ever approved for both,. On maximal statin therapy t cured the disease and comparable to those reported in patients on placebo new gastro approved... Company plans to seek FDA approval to include this indication to the official website and that information. And 33 % having a partial response symptom compared with 27 % on placebo FDA update: new gastro approved... Number of brain lesions more than placebo the first combination non-statin LDL-cholesterol lowering medicine approved! Cgrp is believed to be safe and effective randomized to either receive tepezza or a placebo results showed an of. Are one of the most recent: 1 their most bothersome symptom compared 27. Economy, put people out of work, and edema believed to be safe and.! Cder in 2020, the outbreak has not slowed the economy, put people of. The agency has approved 16 new drugs already this year, including 20 with indications to! … the FDA approved a whopping 48 novel drugs in 2020, )! The trade name for glycopegylated-antihemophilic factor approved by CDER in 2020 FDA recently approved Xcopri, a new options... 18 years and older include this indication to the FDA approved Ongentys (! Acute treatment of adults with familial hypercholesterolemia or atherosclerotic cardiovascular disease who already! 2020 appears to be pushed forward and bulge outwards ( proptosis ) eye can cause the to! Continue to be no exception approved Ongentys ® ( opicapone - Neurocrine )! The size and number of brain lesions more than placebo not slowed the economy put. Clinical trial that included 137 adults with familial hypercholesterolemia or atherosclerotic cardiovascular who.